source
- NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…
- Longevity startup NewLimit secures $435 million Series C as it prepares first liver drug trialNewLimit, a longevity‑focused biotech founded in 2021, announced a Series C financing that brought in $435 million, pushing its valuation to about $3.1 billion. The round was led by Founders Fund…